Serotype-specific pneumococcal antibody concentrations in children treated for acute leukaemia

Area of Science:

• Pediatric Oncology
• Infectious Diseases
• Immunology

Background:

• Children undergoing treatment for acute leukaemia face a heightened risk of Streptococcus pneumoniae infections.
• Reduced levels of pneumococcal antibodies are suspected as a contributing factor, though not extensively studied.

Purpose of the Study:

• To assess serotype-specific pneumococcal IgG antibody concentrations in children post-treatment for acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML).
• To determine if antibody levels are protective against Streptococcus pneumoniae.

Main Methods:

• Measurement of serotype-specific pneumococcal IgG antibody concentrations.
• Analysis conducted in children at least 6 months after completing standard-dose chemotherapy for ALL and AML.
• Comparison of antibody levels between ALL and AML patient groups.

Main Results:

• Children treated for ALL and AML exhibited low pneumococcal serotype-specific IgG antibody concentrations.
• No participants achieved protective antibody concentrations against all serotypes covered by the heptavalent pneumococcal conjugate vaccine.
• No significant differences in antibody concentrations were observed between ALL and AML subjects (p≥0.05).

Conclusions:

• Children treated for acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML) generally possess non-protective antibody concentrations against Streptococcus pneumoniae.
• The findings underscore the significant morbidity from pneumococcal disease in this vulnerable population.
• There is a clear need for effective vaccination strategies to mitigate pneumococcal infection risks in these children.